Alnylam begins DISCOVERY trial to track TTR mutation prevalence
Alnylam Pharmaceuticals has started the DISCOVERY trial of its investigational candidate ALN-TTRsc, to evaluate the prevalence of transthyretin (TTR) mutations in patients suspected of cardiac amyloidosis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Amyloidosis | Pharmaceuticals